Laidlaw started coverage on shares of Athenex, Inc. (NASDAQ:ATNX) in a research note issued on Tuesday. The firm set a “buy” rating and a $36.00 price target on the stock. Laidlaw’s price objective would indicate a potential upside of 111.39% from the company’s current price.

A number of other equities research analysts have also recently commented on ATNX. Deutsche Bank AG assumed coverage on Athenex in a research note on Monday, July 10th. They set a “buy” rating and a $20.00 price objective for the company. Credit Suisse Group initiated coverage on Athenex in a report on Monday. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, Royal Bank Of Canada initiated coverage on Athenex in a report on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price target on the stock.

Shares of Athenex (NASDAQ ATNX) opened at 17.03 on Tuesday. The stock has a 50 day moving average price of $16.17 and a 200 day moving average price of $16.50. Athenex has a one year low of $11.21 and a one year high of $20.79. The firm’s market cap is $971.78 million.

Athenex (NASDAQ:ATNX) last released its earnings results on Monday, August 14th. The company reported ($0.88) EPS for the quarter. The firm had revenue of $4.60 million during the quarter. On average, equities research analysts forecast that Athenex will post ($2.20) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Athenex, Inc. (ATNX) Coverage Initiated by Analysts at Laidlaw” was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/19/athenex-inc-atnx-coverage-initiated-by-analysts-at-laidlaw.html.

Several large investors have recently added to or reduced their stakes in ATNX. Bank of New York Mellon Corp acquired a new stake in shares of Athenex in the second quarter valued at about $240,000. Tudor Investment Corp ET AL acquired a new stake in shares of Athenex in the second quarter valued at about $320,000. Goldman Sachs Group Inc. acquired a new stake in shares of Athenex in the second quarter valued at about $601,000. California Public Employees Retirement System acquired a new stake in shares of Athenex in the second quarter valued at about $800,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Athenex in the second quarter valued at about $800,000. 0.88% of the stock is currently owned by institutional investors and hedge funds.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.